Alliance A151216 (Lung Cancer)

What is the Purpose of this Study?

If you choose to join this study, you will:
- Answer questionnaires
- Have blood draws
- Have tissue samples taken
- Possibly be eligible to join another clinical trial, depending on the results of your genetic testing
- Be contacted by the study team every 6 months for 5 years
What is the Condition Being Studied?
Genetic testing for patients with lung cancer that has been removed or can be removed by surgery

Who Can Participate in this Study?

Adults 18 years and older who:

- Have lung cancer that has been removed by surgery or can be removed by surgery

- Have not received chemotherapy or radiation before surgery

- Are not pregnant

- Do not have recurrent lung cancer

Age Group
Adults
Participating Institutions
Duke Women's Cancer Care Raleigh (Macon Pond)
Johnston Health (Smithfield)
Southeastern Regional Medical Center (Lumberton -Duke site)
Duke Cancer Center Cary
Lexington Medical Center
Duke University Health System
Duke Raleigh Hospital
Scotland Health Care System (Laurinburg)
Maria Parham Health (Henderson)

What is Involved?

We are doing this study to research the genes of patients with lung cancer that has been or will be removed by surgery for a chance to get treatment in a clinical trial.

Study Details

Full Title
Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Principal Investigator
Jeffrey Crawford
George Barth Geller Distinguished Professor for Research in Cancer

Contacts
Protocol Number
IRB:
PRO00057971

NCT:
NCT02194738
ClinicalTrials.gov
View on ClinicalTrials.gov